Haemdall
Research type
Research Study
Full title
Haemdall: Developing a quantitative MRI biomarker of classical (infratentorial) superficial siderosis of the central nervous system
IRAS ID
342971
Contact name
David Werring
Contact email
Sponsor organisation
Perspectum Ltd
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Superficial siderosis is a rare, progressive condition effecting the brain, spine and nerves. The condition results from the gradual deposition of iron that is due to a slow, low volume bleed. The accumulation of iron increases to toxic levels that lead to irreversible nerve damage.
At present, there is a large unmet need for superficial siderosis patients in diagnosing and treating the condition. Superficial siderosis is diagnosed via magnetic resonance imaging (MRI) and visual monitoring of iron level fluctuations, which present as thick black or white lines on the surface of the brain. Currently, there is no method to measure the level of iron, or iron accumulation rate. Methods using qualitative MRI only describe visible iron and require an experienced clinician to diagnose the disease. Despite scans appearing to have no change, toxic damage may be occurring.
To fulfil this unmet need, quantitative MRI (qMRI) will be used to measure iron levels on the brain. Sensitive and precise biomarkers of iron accumulation would accurately identify disease progression, symptom changes and identify when patients would benefit from intervention with iron chelation therapy.
The scan analysis would inform the patient of their iron levels of the whole brain and in regions of interest. The principal aim is to develop a biomarker of brain iron using quantitative MRI for clinical use. By providing the quantity of brain iron and potential foresight of deterioration, we can improve patient care.
REC name
London - Hampstead Research Ethics Committee
REC reference
24/PR/1441
Date of REC Opinion
23 Dec 2024
REC opinion
Further Information Favourable Opinion